Analyst Research

Report Title Price
Trading Report for (PFE). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
$58.00
Buy
Pfizer Inc (PFE) Profile and Financials, plus Nanotechnology Industry Trends Analysis, Operating Ratios and Financial Averages
Provider: Plunkett Research, Ltd.
$99.00
Buy
Pfizer Inc (PFE) Profile and Financials, plus Biotechnology Industry Trends Analysis, Operating Ratios and Financial Averages
Provider: Plunkett Research, Ltd.
$99.00
Buy
Pfizer Inc (PFE) Profile and Financials, plus Health Care Industry Trends Analysis, Operating Ratios and Financial Averages
Provider: Plunkett Research, Ltd.
$99.00
Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Pfizer Inc Announces FDA Approved Lyrica


Thursday, 21 Jun 2012 07:00am EDT 

Pfizer Inc announced that the U.S. Food and Drug Administration (FDA) approved the use of Lyrica (pregabalin) capsules CV for the management of neuropathic pain associated with spinal cord injury. Lyrica received a priority review designation for this new indication from the FDA. 

Latest Developments for Pfizer Inc

Latest Key Developments in Pharmaceuticals

Company Quote

Pfizer Inc
(PFE.N)
29.04
-0.07 -0.24%
12:45pm EDT